Cargando…
Regenerative Cardiovascular Therapies: Stem Cells and Beyond
Although reperfusion therapy has improved outcomes, acute myocardial infarction (AMI) is still associated with both significant mortality and morbidity. Once irreversible myocardial cell death due to ischemia and reperfusion sets in, scarring leads to reduction in left ventricular function and subse...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470623/ https://www.ncbi.nlm.nih.gov/pubmed/30901815 http://dx.doi.org/10.3390/ijms20061420 |
_version_ | 1783411840020119552 |
---|---|
author | Wernly, Bernhard Mirna, Moritz Rezar, Richard Prodinger, Christine Jung, Christian Podesser, Bruno K. Kiss, Attila Hoppe, Uta C. Lichtenauer, Michael |
author_facet | Wernly, Bernhard Mirna, Moritz Rezar, Richard Prodinger, Christine Jung, Christian Podesser, Bruno K. Kiss, Attila Hoppe, Uta C. Lichtenauer, Michael |
author_sort | Wernly, Bernhard |
collection | PubMed |
description | Although reperfusion therapy has improved outcomes, acute myocardial infarction (AMI) is still associated with both significant mortality and morbidity. Once irreversible myocardial cell death due to ischemia and reperfusion sets in, scarring leads to reduction in left ventricular function and subsequent heart failure. Regenerative cardiovascular medicine experienced a boost in the early 2000s when regenerative effects of bone marrow stem cells in a murine model of AMI were described. Translation from an animal model to stem cell application in a clinical setting was rapid and the first large trials in humans suffering from AMI were conducted. However, high initial hopes were early shattered by inconsistent results of randomized clinical trials in patients suffering from AMI treated with stem cells. Hence, we provide an overview of both basic science and clinical trials carried out in regenerative cardiovascular therapies. Possible pitfalls in specific cell processing techniques and trial design are discussed as these factors influence both basic science and clinical outcomes. We address possible solutions. Alternative mechanisms and explanations for effects seen in both basic science and some clinical trials are discussed here, with special emphasis on paracrine mechanisms via growth factors, exosomes, and microRNAs. Based on these findings, we propose an outlook in which stem cell therapy, or therapeutic effects associated with stem cell therapy, such as paracrine mechanisms, might play an important role in the future. Optimizing stem cell processing and a better understanding of paracrine signaling as well as its effect on cardioprotection and remodeling after AMI might improve not only AMI research, but also our patients’ outcomes. |
format | Online Article Text |
id | pubmed-6470623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64706232019-04-26 Regenerative Cardiovascular Therapies: Stem Cells and Beyond Wernly, Bernhard Mirna, Moritz Rezar, Richard Prodinger, Christine Jung, Christian Podesser, Bruno K. Kiss, Attila Hoppe, Uta C. Lichtenauer, Michael Int J Mol Sci Review Although reperfusion therapy has improved outcomes, acute myocardial infarction (AMI) is still associated with both significant mortality and morbidity. Once irreversible myocardial cell death due to ischemia and reperfusion sets in, scarring leads to reduction in left ventricular function and subsequent heart failure. Regenerative cardiovascular medicine experienced a boost in the early 2000s when regenerative effects of bone marrow stem cells in a murine model of AMI were described. Translation from an animal model to stem cell application in a clinical setting was rapid and the first large trials in humans suffering from AMI were conducted. However, high initial hopes were early shattered by inconsistent results of randomized clinical trials in patients suffering from AMI treated with stem cells. Hence, we provide an overview of both basic science and clinical trials carried out in regenerative cardiovascular therapies. Possible pitfalls in specific cell processing techniques and trial design are discussed as these factors influence both basic science and clinical outcomes. We address possible solutions. Alternative mechanisms and explanations for effects seen in both basic science and some clinical trials are discussed here, with special emphasis on paracrine mechanisms via growth factors, exosomes, and microRNAs. Based on these findings, we propose an outlook in which stem cell therapy, or therapeutic effects associated with stem cell therapy, such as paracrine mechanisms, might play an important role in the future. Optimizing stem cell processing and a better understanding of paracrine signaling as well as its effect on cardioprotection and remodeling after AMI might improve not only AMI research, but also our patients’ outcomes. MDPI 2019-03-21 /pmc/articles/PMC6470623/ /pubmed/30901815 http://dx.doi.org/10.3390/ijms20061420 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wernly, Bernhard Mirna, Moritz Rezar, Richard Prodinger, Christine Jung, Christian Podesser, Bruno K. Kiss, Attila Hoppe, Uta C. Lichtenauer, Michael Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
title | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
title_full | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
title_fullStr | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
title_full_unstemmed | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
title_short | Regenerative Cardiovascular Therapies: Stem Cells and Beyond |
title_sort | regenerative cardiovascular therapies: stem cells and beyond |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470623/ https://www.ncbi.nlm.nih.gov/pubmed/30901815 http://dx.doi.org/10.3390/ijms20061420 |
work_keys_str_mv | AT wernlybernhard regenerativecardiovasculartherapiesstemcellsandbeyond AT mirnamoritz regenerativecardiovasculartherapiesstemcellsandbeyond AT rezarrichard regenerativecardiovasculartherapiesstemcellsandbeyond AT prodingerchristine regenerativecardiovasculartherapiesstemcellsandbeyond AT jungchristian regenerativecardiovasculartherapiesstemcellsandbeyond AT podesserbrunok regenerativecardiovasculartherapiesstemcellsandbeyond AT kissattila regenerativecardiovasculartherapiesstemcellsandbeyond AT hoppeutac regenerativecardiovasculartherapiesstemcellsandbeyond AT lichtenauermichael regenerativecardiovasculartherapiesstemcellsandbeyond |